Skip Navigation

JNCI Monographs 2005 2005(34):107-110; doi:10.1093/jncimonographs/lgi023
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Patrizio, P.
Right arrow Articles by Caplan, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Patrizio, P.
Right arrow Articles by Caplan, A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

2005 © Oxford University Press

Ovarian Tissue Preservation and Future Fertility: Emerging Technologies and Ethical Considerations

Pasquale Patrizio, Samantha Butts, Arthur Caplan

Affiliations of authors: Department of Obstetrics and Gynecology—Yale University Fertility Center, New Haven, CT (PP); Department of Obstetrics and Gynecology—Hospital University of Pennsylvania, Philadelphia, PA (SB); Center for Bioethics, University of Pennsylvania, Philadelphia, PA (AC)

Correspondence to: Pasquale Patrizio, MD, MBE, HCLD, Yale Fertility Center, 150 Sargent Drive, 2nd Floor, New Haven, CT 06511 (e-mail: pasquale.patrizio{at}yale.edu).

Both adult women and prepubertal girls facing cancer treatment may have the option to harvest and cryopreserve ovarian tissue. If they have successful therapy for their disease, the tissue may be autotransplanted back into the woman's body or follicles may be harvested and matured in vitro. These techniques all remain experimental, however, and should be performed only by specialized centers that can provide a multidisciplinary team. The procedures should be done under approval from an Institutional Review Board with proper assurance of informed consent. Although the costs for research could be assessed to patients if no research funds are available, clinical fees should not be charged at this stage in the development of these technologies. Consideration should be given to the protection of minors by ensuring parental informed consent and child assent whenever possible. Disposition of cryopreserved gonadal tissue in the event of the participant's death should be formally designated. A registry should be established to follow the health of participants and their eventual offspring.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JCOHome page
S. J. Lee, L. R. Schover, A. H. Partridge, P. Patrizio, W. H. Wallace, K. Hagerty, L. N. Beck, L. V. Brennan, and K. Oktay
American Society of Clinical Oncology Recommendations on Fertility Preservation in Cancer Patients
J. Clin. Oncol., June 20, 2006; 24(18): 2917 - 2931.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.